A Clinical Trial To Check The Efficacy Of Karkashchadadi Kwath In Medodushti (Dyslipidemia)
- Conditions
- Health Condition 1: E785- Hyperlipidemia, unspecified
- Registration Number
- CTRI/2023/07/054923
- Lead Sponsor
- Shri Krishna Govt. Ayurvedic College and Hospital. Kurukshetra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
i. Patients willing to sign the consent form.
ii. Patients between the age group of 25-60 years of either sex.
iii. Patients having underweight, normal weight, overweight, and class I obesity according to BMI
iv. Diagnosed & confirmed cases of Medodushti (Dyslipidemia) & Medoroga on the basis of criteria
given by NCEP-ATPIII. (Borderline High category).
a) Patient not fulfilling inclusion criteria.
b) Patient not willing for clinical trial.
c) Patient below 25yrs of age group and above 65yrs of age group.
d) Patients having medical history of -
Unstable angina, Myocardial Infarction, Heart failure or stroke.
e) Uncontrolled Hypertension (Diastolic Blood Pressure > 100 mmHg).
f) Uncontrolled Diabetes Mellitus.
g) Impaired Renal Function (Creatinine > 2 mg/dl).
h) ALT and AST >3 times of upper limit of normal.
i) Patient on steroid therapy and oral contraceptive therapy.
j) Pregnant and lactating patient.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The effect of drug will be analyzed on 1st 15th 30th 45th 60th day & after treatment by the means of change in subjective criteria & objective criteria (body weight, BMI, CBC, Lipid profile , SGOT, SGPT, Serum creatinine , FBS, Urine Routine & Microscopy,Timepoint: Approximate 60days per patient
- Secondary Outcome Measures
Name Time Method 1. To determine the effect of drug on clinical parameters & biochemical findings associated <br/ ><br>with Medodushti (Dyslipidemia). <br/ ><br>2. To advise preventive measures to check the occurrence of disease in individual and masses. <br/ ><br>3. To standardize the ayurvedic line of treatment, both drug and dose which may have effective <br/ ><br>role in management of patients of Medodushti (Dyslipidemia). <br/ ><br>4. To explain the Medodushti (Dyslipidemia) critical review on the basis of classical text of <br/ ><br>ayurveda and with the help of modern literature. <br/ ><br>5. To provide cheap, safe, and effective treatment from ayurveda to Dyslipidemic patients. <br/ ><br>6. To rule out secondary causes that count for lipoprotein disorder. <br/ ><br>7. To prevent the complication of Dyslipidemia like atherosclerosis, CAD, CVD & PVD. <br/ ><br>Timepoint: 2 year